How Cosmetic Injectable Products are Regulated in Australia

Why the TGA is Involved at All

Cosmetic injectable products, including the products commonly used for anti-wrinkle treatment, dermal filler treatment, and hyperhidrosis treatment, are not cosmetics in the regulatory sense. They are therapeutic goods because they are introduced into the body to alter physiological function or to be used in clinical procedure.

The Therapeutic Goods Administration is the federal regulator for therapeutic goods in Australia. Its scope includes prescription medicines, over-the-counter medicines, vaccines, blood products, medical devices, and the products used in cosmetic injectable treatment.

This classification has practical effects. The products cannot be supplied directly to consumers. They cannot be advertised to the public in the way cosmetics can. They must be administered by registered practitioners under appropriate prescription. Adverse events must be reportable. These are not optional standards for the practitioner; they are the regulatory framework within which any compliant cosmetic injectable clinic operates.

The Schedule 4 Classification

The products used in cosmetic injectable treatment are classified as Schedule 4 medicines under the Standard for the Uniform Scheduling of Medicines and Poisons. Schedule 4 means: prescription-only.

In practice this means: a registered medical practitioner or nurse practitioner must write the prescription. The patient cannot obtain the product directly from a pharmacy without that prescription. The product must be administered by a registered health practitioner with appropriate training. The supply chain from manufacturer to administration is documented and traceable.

For patients, this is part of why the consultation conversation includes prescription discussion. The practitioner is not just recommending a treatment; they are arranging for a prescribed medicine to be administered. Where the practitioner is a registered nurse rather than a medical practitioner, prescription oversight comes from a collaborating prescriber within the regulatory framework.

Advertising Restrictions Under the Therapeutic Goods Advertising Code

Cosmetic injectable products cannot be advertised to consumers in the way cosmetics or other consumer products can. The Therapeutic Goods Advertising Code prohibits: patient testimonials about the service or product, before-and-after imagery of identifiable patients, brand-name product promotion, outcome guarantees, superlative or emotional inducement, discount or time-limited pricing structures, and any advertising that suggests the products are routine or risk-free.

This is why cosmetic injectable clinic websites and consultation materials look different from beauty salon or cosmetic product marketing. The restrictions are not stylistic choices. They are mandatory under the Code, with significant penalties for breach.

For patients, the restrictions are protective. Testimonials and before-and-after imagery, where they appear in cosmetic injectable advertising, are typically a sign that the clinic is not operating within the Code. Discount pricing and time-limited offers are similarly non-compliant.

Practitioner Registration Requirements

The TGA framework intersects with AHPRA, the practitioner regulator. Cosmetic injectable products may only be administered by practitioners who are: registered with AHPRA, in current practice with active registration, working within the scope of their training and competence, and meeting any specific guidelines AHPRA has issued for cosmetic procedures.

The AHPRA September 2025 guidelines for non-surgical cosmetic procedures set additional standards including consultation-first treatment for new patients, mandatory cooling-off periods, advertising compliance specific to cosmetic procedures, and continuing professional development requirements specific to the practitioner’s scope.

Where a clinic operates with practitioners who are not AHPRA-registered or are practising outside their scope, the entire treatment chain is non-compliant. Patients can verify a practitioner’s registration via the AHPRA public register. The registration number for the practitioner at Core Aesthetics is NMW0001047575 (Corey Anderson, registered nurse).

How Adverse Events are Reported

Serious adverse events from therapeutic goods are reportable to the TGA under the Therapeutic Goods Act. The reporting requirement applies to: registered practitioners who become aware of adverse events, sponsors and manufacturers of the products involved, and consumers (although consumer reports are typically channeled through the practitioner).

Reportable events include: unexpected outcomes that meet defined seriousness thresholds, vascular events, infections, allergic reactions, and any event resulting in hospitalisation or significant clinical consequence.

The reporting framework supports broader safety monitoring of products in the Australian market. Where the same adverse event pattern is reported by multiple practitioners, the TGA can investigate the product, the manufacturer, or specific batches. This is one of the safety mechanisms that makes the regulated market safer than unregulated alternatives.

Supply Chain Integrity

The supply chain for cosmetic injectable products is regulated end-to-end. Manufacturers must be TGA-licensed. Sponsors (the local entity responsible for the product in Australia) must be registered. Distribution must be through TGA-approved channels. Pharmacy storage must meet temperature and handling requirements. Administration must be documented in clinical records.

Products purchased outside this regulated chain (grey market, online imports, products from non-pharmacy sources) are non-compliant and present significant patient safety risks. The product may be: counterfeit, expired, improperly stored, mislabeled, or substituted.

For patients, supply chain integrity is largely invisible because it is the practitioner’s responsibility. However, the implications are visible in: the practitioner’s willingness to discuss product source, the documentation provided in the clinical record, and the consistency of pricing with regulated supply costs. Significantly below-market pricing for cosmetic injectables is sometimes a sign of non-compliant supply.

Why Brand Names are Not Used in Public Advertising

The Therapeutic Goods Advertising Code prohibits public advertising that promotes specific brand names of Schedule 4 medicines. This applies to cosmetic injectable products as it applies to other prescription medicines.

This is why compliant cosmetic injectable clinics do not name specific products in their public materials. The product is discussed in clinical class terms (anti-wrinkle injection, dermal filler) rather than by brand. Brand-specific information is shared at consultation in the clinical record, where it forms part of the prescription and informed consent conversation, but not in public advertising.

Clinics that prominently feature brand names in their advertising are typically operating outside the Code. The branded language can also confuse patients into believing one brand is uniformly superior to others, when clinical decisions about which product to use are individualised based on the area, the patient’s anatomy, and the practitioner’s experience.

How Pricing Restrictions Work

TGA Therapeutic Goods Advertising Code restrictions on pricing for cosmetic injectables include: no discount-based promotion, no time-limited offers, no pricing structures designed to encourage immediate decisions, no inducement-based marketing.

The protective rationale is to prevent financial pressure compromising informed consent. A patient who feels they need to decide today to avoid losing a discount is not in a position to make a considered decision about a Schedule 4 medical procedure.

Compliant pricing for cosmetic injectables is: discussed transparently at consultation, consistent across patients with comparable clinical scope, free of time pressure, and decoupled from the consultation fee (which is charged separately so the cost of consultation does not function as a barrier to declining recommended treatment).

How Patient Consent Sits Within the Framework

The TGA framework requires informed consent for any administration of Schedule 4 medicines. The AHPRA framework adds specific consent requirements for non-surgical cosmetic procedures. The combined effect is that informed consent is documented, specific, and renewed at each appointment.

The documented consent typically includes: identification of the specific product, the anatomical area to be treated, the dose, the technique, the expected outcome, the known risks at general and product-specific level, the alternatives including no treatment, and the cost and review structure.

Consent is not a one-off form. It is a structured conversation with documentation at each treatment visit. This depth of consent is part of why a single appointment in a regulated cosmetic injectable clinic takes longer than a typical cosmetic service appointment in an unregulated context.

Why the Framework Exists

The TGA and AHPRA frameworks exist because cosmetic injectable products carry real clinical risks. Vascular events, infections, allergic reactions, and other adverse events can result in significant harm. The products work by altering physiological function in ways that are not trivially reversible. Patient outcomes depend significantly on practitioner technique, product quality, and clinical judgement.

The regulatory framework is the mechanism through which Australian patients have substantially safer access to these products than would be the case in a less-regulated environment. The framework also creates the conditions under which compliant practitioners can build trust with patients over time, because the basic standards of safety, consent, and transparency are established by regulation rather than by individual clinic preference.

Where clinics operate outside the framework, patients are exposed to elevated risk that is not generally visible in the consultation experience itself. This is part of why understanding the framework is useful for patients comparing clinics.

How to Verify a Clinic Operates Within the Framework

Verification involves several practical checks. First, verify the practitioner’s AHPRA registration through the public register at ahpra.gov.au. The register shows the registration status, the scope of practice, and any conditions on the registration.

Second, observe whether the clinic’s advertising and consultation conversations comply with the Code: no patient testimonials, no before-and-after imagery of identifiable patients, no brand-name product promotion in public materials, no discount pricing or time-limited offers, no outcome guarantees, no superlatives or emotional inducement language.

Third, observe whether the consultation includes a structured cooling-off period for new patients in line with AHPRA September 2025 guidance. Same-day treatment for new patients is a non-compliant pattern.

Fourth, observe whether the clinic provides documented informed consent at each treatment, with discussion of the specific product, dose, area, and known risks. Where consent is treated as paperwork rather than conversation, that is a sign of non-compliance.

How This Operates at Core Aesthetics

Core Aesthetics operates within both the TGA Therapeutic Goods Advertising Code and the AHPRA September 2025 guidelines for non-surgical cosmetic procedures. The clinic is operated by Corey Anderson, AHPRA registered nurse, NMW0001047575, with prescription oversight under the standard regulatory framework for nurse-administered Schedule 4 medicines.

First appointments are consultations. Treatment is scheduled at subsequent appointments after the cooling-off period. Advertising is consistent with the Code: no testimonials, no before-and-after imagery, no brand names, no discount pricing. Consent is documented at each treatment. Adverse event protocols are in place. Continuing professional development is documented for the practitioner’s annual registration.

The regulatory framework is not an inconvenience to the clinic; it is the structure within which the clinic operates. Patients benefit from this structure because it establishes baseline safety, consent, and transparency standards that are otherwise dependent on individual clinic preference.